NeuroTidal Dx

Parkinson’s Disease affects 10 million people globally, with cases expected to double by 2050. Over the last five years, 1000 clinical trials have been performed, yet still there is no cure. Current diagnostic methods are subjective and fail to align with underlying pathological changes. This is a key obstacle in drug development as it results in 1) unclear readout of treatment efficacy and 2) too late detection of the disease, when irreversible brain damage has already been done. At NeuroTidal Dx we provide a novel for objective measurement and earlier detection. We will offer initially a service to support clinical trials. NeuroTidal’s technology is based on the deep understanding of the molecular mechanisms of the disease in our internationally leading laboratory in protein chemistry of disease, from which the enthusiastic NeuroTidal team emerged. Our patented FibrilRuler test addresses unmet diagnostic need by determining the size of α-synuclein amyloid fibrils, the key pathological hallmark of Parkinson’s Disease, at nm resolution. These fibrils grow with progressing pathology, which FibrilRuler accurately measures in body fluids like blood and CSF - from earliest precursors to the end state of the disease. In doing so, we transform this hallmark into a direct and quantitative biomarker. We cooperate with ProPark, the largest Dutch Parkinson consortium, to validate the FibrilRuler test in retrospective clinical studies. FibrilRuler is the first and only test to objectively stage disease of the full Parkinson’s timeline. We will further extend our application to related amyloid diseases, such as Alzheimer’s, and subsequently develop the FibrilRuler technology into screening kits for healthcare laboratories. We need 1M investment to get to the market, with projected revenue of 10M in 2031. In the long-term, we aim to provide the gold standard in diagnostics of neurodegenerative diseases.